GlassScriptPhysician profile
Curtis M Libby
NPI 1275534489
$5,217.99
in general payments reported to CMS, 2019-2025
20 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $335 · 2021: $954 · 2022: $1,535 · 2023: $667 · 2024: $592 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $1,560.35 | 2019-2022 | |
| Abbvie INC. | $933.41 | 2022-2025 | |
| Glaukos Corporation | $789.82 | 2019-2023 | Photrexa Cross-Linking Kit |
| Alcon Vision LLC | $672.14 | 2019-2025 | Clareon, Lensx, Rocklatan |
| Sight Sciences, INC. | $371.48 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $347.59 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $141.17 | 2024-2025 | Envista Envy Iol, Vyzulta, Miebo |
| Ivantis, INC | $96.01 | 2021 | |
| Novartis Pharmaceuticals Corporation | $68.19 | 2019-2023 | |
| Genentech USA, INC. | $37.77 | 2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $28.35 | 2025 | Eylea Hd |
| Oyster Point Pharma, INC. | $27.06 | 2024 | Tyrvaya |
| Astellas Pharma US INC | $25.01 | 2025 | Izervay |
| Rxsight INC | $23.27 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.96 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $19.70 | 2019 | |
| Eyepoint US, INC. | $18.65 | 2019 | |
| Apellis Pharmaceuticals, INC. | $18.59 | 2025 | Syfovre |
| New World Medical,INC. | $16.64 | 2023 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,631.01 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Libby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.